Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of palbociclib when given alone and
in combination with sorafenib, decitabine, or dexamethasone in treating patients with
leukemia that has come back (recurrent) or that does not respond to previous treatment
(refractory). Palbociclib, sorafenib, and decitabine may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
dexamethasone, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
palbociclib alone and in combination with sorafenib, decitabine, or dexamethasone may work
better in treating patients with recurrent or refractory leukemia.